Page 3 - Glaxosmithkline

GSK Consumer's pre-tax profit up 6% in Q2 on controlled raw material costs

According to the company, its domestic business grew 7 per cent, backed by Horlicks' and Boost's performance

GSK suspends sale of antacid Zinetac after USFDA issues advisory

Indian drugmakers have also started testing their ranitidine products at various laboratories after the US FDA issued an advisory on the drug to health care professionals

Drug major GSK sold off up to 10 tail-end brands in FY19 including Celin

According to the firm's FY19 annual report, it fetched Rs 5 crore during the year from the sale of brands

Bharat Biotech to buy GSK's Indian arm that produces anti-rabies vaccine

Bharat Biotech chairman Krishna Ella said the acquisition of Chiron Behring would make the company world's largest producer of anti-rabies vaccine

Pfizer Inc deal with GlaxoSmithKline plc will have no India impact

Ruling out any impact on GSK's India business, company sources said in India the pharma entity owned and manufactured products such as Iodex and Ostocalcium, which were marketed by GSK Consumer

Pharma giant GSK buys US cancer drugmaker Tesaro for hefty $5.1 bln

Tesaro boosts GSK's pharma portfolio at high price $75/ share; cash from Horlicks sale to help fund pharma investment

Glaxo seeks mid-Sept bids for $4 billion Indian Horlicks unit: Report

The company is assessing its 72.5 per cent holding in India-listed GlaxoSmithKline Consumer Healthcare Ltd. as part of that process

GlaxoSmithKline may split up group, spin off consumer division: Report

Some investors have long called for the group's break-up, arguing that it would crystallise value for component businesses